The potential role of the HIV-1 immunogen (Remune®) as a therapeutic vaccine in the treatment of HIV infection

Expert Review of Vaccines

Volumn 2, Issue 6, 2003, Pages 739-752

  Fernández Cruz, Eduardo ^a   Navarro, Joaquín ^a   Rodríguez Sainz, Carmen ^a   Gil, Juana ^a   Moreno, Santiago ^b   González Lahoz, Juan ^c   Carbone, Javier ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antiretroviral drugs; Clinical trial; CTL responses; HIV 1; Immune based therapies; Immunogen; Lymphoproliferative responses; Remune; Safety profile; Therapeutic vaccination; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOKINE; DIDANOSINE; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; LAMIVUDINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NELFINAVIR; NEVIRAPINE; PROPIOLACTONE; RANTES; RITONAVIR; STAVUDINE; ZIDOVUDINE;

CHILL; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DRUG SAFETY; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKINESIA; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOTHERAPY; INFLAMMATION; INJECTION PAIN; MIXED LYMPHOCYTE CULTURE; NECK PAIN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SHOULDER PAIN; SPAIN; THAILAND; UNITED STATES; VACCINATION; VIRUS LOAD;

EID: 0346849716     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.6.739     Document Type: Review

References (92)

1. Eberle J, Bechowsky B, Rose D et al. Resistance of HIV type 1 protease inhibitor RO 31-8959. AIDS Res. Hum. Retroviruses 11, 671-676 (1995).
2. Condra J, Schleif, Blahy O et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569-571 (1995).
3. Tisdale M, Myers RE, Maschera B. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimic. Ag. Chem. 39, 1704-1710 (1995).
4. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, Department of Health and Human Services, February 4, 2002.
5. Mellors JW, Rinaldo CR Jr, Gupta P et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272 (5265), 1167-1170 (1996).
6. Benito JM, Zabay JM, Gil J et al. Quantitative alterations of the functionally distinct subsets of CD4 and CD8 T lymphocytes in asymptomatic HIV infection: changes in the expression of CD45RO, CD45RA, CD11b, CD38, HLA-DR, and CD25 antigens. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 14(2), 128-135 (1997).
7. + T-cells and that CD4 T-cell proliferative responses correlated with reductions in plasma viral load.
8. Carbone J, Gil J, Benito JM et al. Increased levels of activated subsets of CD4 T cells add to the prognostic value of low CD4 T cell counts in a cohort of HIV-infected drug users. AIDS 14(18), 2823-2829, (2000).
9. Valdez H, Smith KY, Landay A et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trial Group. AIDS 14 (1), 11-21 (2000).
10. + T cell homeostasis and function in advanced HIV disease. Science 277 (5322), 112-116 (1997).
11. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med. 5 (5), 518-525 (1999).
12. Rinaldo CR Jr, Liebmann JM, Huang XL et al. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J. Infect. Dis. 179(2), 329-336 (1999). Demonstrates that antiretroviral therapy alone does not have the ability to completely reconstitute specific immunologic responses to HIV-1.
13. + T-specific helper cells.
14. Angel JB. Improving immune function and controlling viral replication in HIV-1-infected patients with immune-based therapies. AIDS 11(4), 209-21 (2001).
15. Klein MR, van Baalen CA, Holwerda AM et al. Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181, 1365-1372 (1995).
16. Rinaldo C, Huang X-L, Fan Z et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long-term nonprogressors. J. Virol. 69, 5838-5842 (1995).
17. Alkhatib G, Combadiere C, Broder C et al. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272, 1955-1958 (1996).
18. Deng H, Liu R, Ellmeier W et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381, 661-666 (1996).
19. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381, 667-673 (1996).
20. + T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous β-chemokines and the viral inductive effects of other endogenous cytokines. Proc. Natl Acad. Sci. 93, 14076-14081 (1996).
21. Gruters RA, van Baalen CA, Osterhaus AD. The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes. Vaccine 20 (15), 2011-2015 (2002).
22. Wodarz D. The persistence of CTL memory. Neth. J. Med. 60(Suppl. 7), 4-13 (2002).
23. Lieberman J, Shankar P, Manjunath N et al. Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood 98(6), 1667-1677 (2001).
24. Goebel FD, Mannhalter JW, Belshe RB et al. Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized. AIDS 13(12), 1461-1468 (1999).
25. Cox JH, Garner RP, Redfield RR et al. Antibody-dependent cellular cytotoxicity in HIV type 1-infected patients receiving VaxSyn: a recombinant gp160 envelope vaccine. AID. Res. Hum. Retroviruses 15(9), 847-854 (1999).
26. Schooley RT, Spino C, Kurizkes D et al. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-infected individuals across a spectrum of disease severity. AIDS Clinical Trials Groups 209 and 214. J. Infect. Dis. 182(5), 1357-1364 (2000).
27. Wright PF, Lambert JS, Gorse GJ et al. Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women. J. Infect. Dis. 180(4), 1080-1088 (1999).
28. + cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine. Proc. Natl Acad. Sci. USA. 89(23), 11204-11208 (1992).
29. Pinto LA, Berzofsky JA, Fowke KR et al. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS 13(15), 2003-2012 (1999).
30. Birx DL, Loomis-Price LD, Aronson N et al. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers: rgp 160 phase II vaccine investigators. J. Infect. Dis. 181 (3), 881-890 (2000).
31. Sandstrom E, Wahren B. Therapeutic immunization with recombinant gp160 in HIV-1 infection: a randomized doubleblind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet 353(9166), 735-742 (1999).
32. DeMaria Jr A, Kunches L, Mayer K et al. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gp160 vaccine among adults with advanced HIV infection: Massachussetts gp160 Working Group. J. Hum. Virol. 3(4), 182-192 (2000).
33. Kalzenstein DA, Kundu S, Spritzler J et al. Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rcp160) afer immunization with homologous antigen. J. Acquired Immune Defic. Syndr. 22(4), 341-347 (1999).
34. Churdboonchart V, Moss RB, Sirawarapon W et al. Effect of HIV-specific immune based therapy in subjects infected with HIV-1 subtype E in Thailand. AIDS 12 (2), 1521-1527(1998).
35. Kahn JO, Cherng DW, Mayer K et al. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 × 10(6)/L CD4 cell counts: A randomized controlled trial. JAMA 284(17), 2193-2202 (2000). An American Phase III study specifically designed to examine the effects of Remune on clinical endpoints. Co-treatment with potent antiretroviral agents make the results of this large-scale study difficult to interpret.
36. + T-specific helper cell responses.
37. Peters BS, Cheingsong-Popov R, Callow D et al. A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV serpositive subjects. J. Infect. 35 (3), 231-235 (1997).
38. Benson EM, Clarkson J, Law M et al. Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals. AIDS Res. Hum. Retroviruses 15(2), 105-113 (1999).
39. Lindenburg CE, Stolte I, Langendam NM et al. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24: Ty virus-like particles on HIV-1 disease progression. Vaccine 20(17-18), 2343-2347 (2002).
40. Seth A, Yaustomi Y, Jacoby H et al. Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals. AIDS Res. Hum. Retroviruses 16(4), 337-343 (2000).
41. Gringeri A, Santagostino E, Muca-Perja M et al. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. J. Hum. Virol. 1(4), 293-298 (1998).
42. Asjo B, Stavang H, Sorensen B et al. Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy. AIDS Res. Hum. Retroviruses 18(18), 1357-65 (2002).
43. Jin X, Ramanathan Jr M, Barsoum S et al. Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J. Virol. 76(5), 2206-2216 (2002).
44. Tubiana R, Carcelein G, Vray M et al. Therapeutic vaccination with ALVAC-HIV vCP1433: A recombinant Canarypox vaccine in chronically HIV-1 infected patients with HAART. VAAITER (ANRS 094). Proceedings of the 10th Conference on Retroviruses and Oportunistic Infections, Boston, USA (2003).
45. Harrer E, Bäuerle M, Ferstl B et al. Phase-I Study with a therapeutic MVA-BN-Nef Vaccine in HIV-1 infected patients on HAART. Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2003).
46. McDowell WM, Askari FK. DNA vaccines. N. Engl. J. Med. 334(1), 42-45 (1996).
47. + T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19(7-8), 764-778 (2000).
48. MacGregor RR, Boyer JD, Ugen KE et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J. Infect. Dis. 178(1), 92-100 (1998).
49. Dorrell L, Yang H, Conlon CP et al. Safety and immunogenicity of a candidate HIV-1 DNA Gag/Multi-epitope vaccine, pTHr.HIVA in HIV-1 Seropositive Subjects Receiving HAART. Proceedings of the 10th Conference on Retroviruses and Oportunistic Infections. Boston, USA (2003).
50. Lisziewicz J, Bakare N, Lori F. Therapeutic vaccination for future management of HIV/AIDS. Vaccine 21, 600-623 (2003).
51. Fernandez-Cruz E, Navarro J, Abad ML et al. Effect of a gp120-depleted inactivated HIV-1 immunogen (REMUNE®) on the control of Nuclear factor Kappa-B activation, cytokin production and augmentation of HIV-specific cytotoxic T Lymphocytes. Proceedings of the 5th European Conference on Experimental AIDS Research. Madrid, Spain, Abstract W9 (2000). Demonstrates in an immunological model with primary human T-cells that an HIV-1 Immunogen could induce an immunomodulatory effect in the activation of T-cells.
52. Choi DJ, Dube S, Spicer TP et al. HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant. AIDS Res. Hum. Retroviruses 13(4), 357-361 (1997).
53. Prior CP, Gore F, Harter J et al. Inactivation and purification of human immunodeficiency virus-1 as antigen for the treatment of HIV-1 infection. Biopharm 9, 22-34, (1996).
54. Prior C, Bay P, Ebert B, Gore F, Holt J, Irish T et al. Process Development for the manufacture of inactivated HIV-1. Pharmaceutical Technology 8(4), 25-35 (1995).
55. LoGrippo G. Investigations of the use of β-propiolactone in virus inactivation. Ann. NY. Acad. Sci. 83, 578-579, 1960.
56. Kitchen AD, Mann GF, Harrison JF et al. Effect of gamma irradiation on the human. immunodeficiency virus and human coagulation proteins. Vox. Sang. 56(4), 223-229 (1989).
57. Limsuwan A, Churdboonchart V, Moss RB et al. Safety and immunogenicity of REMUNE™ in HIV-infected Thai subjects. Vaccine 16, 142-149 (1997).
58. Churdboonchart V, Sakondhavat C, Kulpradist S et al. A Double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) Immunogen (REMUNE) monotherapy in asymptomatic, HIV-1-infected Thai subjects with CD4-cell counts of >300. Clin. Diagn. Lab. Immunol. 7, 728-733 (2000). The authors show that therapeutic vaccination with an HIV-1 Immunogen (Remune) significantly increases CD4 cell counts compared to those achieved with the adjuvant control in asymptomatic HIV-1-infected subjects not taking antiviral drugs.
59. Sukeepaisarncharoen W, Churdboonchart V, Kulpradist S et al. Long-term follow-up of HIV-1-infected Thai patients immunized with REMUNE monotherapy. HIV Clinical Trials 2, 391-398 (2001).
60. S Moreno, J Gonzalez-Lahoz, J Perez Molina et al. Therapeutic immunization with an inactivated HIV-1 immunogen in naive patients initiating antiretroviral treatment; Final results of a phase II, double-blind, placebo controlled trial (STIR-2102) (STIR2102: Spanish Trial with HIV-1 immunogen, REMUNE). Proceedings of the 14th International AIDS Conference, Barcelona, Spain, Abstract LbA9004 (2002). This European study describes that therapeutic vaccination with the HIV-1 Immunogen (Remune) plus antiretrovirals (ARTs) protected against virological rebound compared to antiretroviral alone.
61. Fernández-Cruz E, Navarro J, Moreno S. 5-year evaluation of a therapeutic vaccine (HIV-1 immunogen) administered with antiretrovirals in patients with HIV chronic infection: Induction of long-lasting HIV-specific cellular immunity that impact on viral load. Proceedings of the 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, Abstract 486 (2003).
62. Fernández-Cruz E, Navarro J, Abad ML et al. Augmentation of HIV-1-specific cytotoxic T lymphocytes and cellular immune responses in HIV-1+ individuals treated with a therapeutic vaccine plus antiretrovirals in a Phase II study: two year results. Proceedings of the XIII International AIDS Conference. Durban, South Africa, A709/C4059 (2000). This study describes that therapeutic vaccination with the HIV-1 Immunogen (Remune) plus ARTs elicited statistically significant high levels of HIV-1 Gag/pol-specific CTL precursors compared with the lack of increase in the placebo arm, which correlated negatively with viral load.
63. + Individuals Treated with a Therapeutic Vaccine plus Antiretrovirals: Impact on Viral Load. Proceedings of the 9th Conference on Retroviruses and Oportunistic Infections, Seattle, WA, USA, Abstract 318W (2002).
64. th Conference on Retroviruses and Oportunistic Infections. Boston, USA, Abstract 641 (2003). This study describes that therapeutic vaccination with the HIV-1 Immunogen (Remune) plus ARTs increases HIV-specific immunological memory responses throughout the whole period of immunization (60 months).
65. Trauger FJ, Ferre F, Daigle A et al. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type I (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J. Infect. Dis. 169, 1256-1264 (1994).
66. Valentine F, De Gruttola V et al. Immunological and virological evaluations of the effects of HAART compared to HAART plus an inactivated HIV immunogen after 32 weeks. 6th Conference on Retroviruses and Oportunistic Infections, Chicago, USA, Abstract 346 (1999).
67. Turner JL, Trauger RJ, Daigle AE et al. HIV-1 immunogen induction of HIV-1-specific delayed-type hypersensitivity: results of a double-blind, adjuvant-controlled, dose-ranging trial. AIDS 8(10), 1429-1435 (1994).
68. Turner JL, Kostman JR, Aguino A et al. The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts, and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomicant antiviral drugs. HIV Med. 2, 1-12 (2001).
69. Clerici M, Berzofsky JA, Shearer GM et al. Exposure to human immunodeficiency virus (HIV) type I indicated by HIV-specific T helper cell responses before detection of infection by polymerase chain reaction and serum antibodies. J. Infect. Dis. 164(1), 178-182 (1991).
70. + T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen. AIDS Res. Hum. Retroviruses 16(6), 539-47 (2000). Describes that individuals who received therapeutic vaccination with the HIV-1 Immunogen had increased CD4 T-cells expressing cytokines in response to HIV-1 antigens in vitro.
71. Moss RB, Wallace MR, Steigbigel RT et al. Predictors otf HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination. Clin. Exp. Immunol. 128(2), 359-364 (2002).
72. Moss RB, Webb E, Giermakowska WK. HIV-1-specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with inactivated gp120-depleted HIV-1 in incomplete Freund's adjuvant. J. Acquir. Immune Defic. Syndr. 24(3), 264-269 (2000).
73. Gilbert PB, DeGruttola VG, Hudgens MG et al. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. J. Infect. Dis. 188(2), 179-193 (2003). The authors suggest that a vaccine demostrating moderately durable effects to delay therapy and to ameliorate viremia merits consideration for licensure.
74. Hudgens MG, Hoering A, Self SG. On the analysis of viral load endpoints in HIV vaccine trials. Stat. Med. 22(14), 2281-2298 (2003).
75. Quinn TC, Wawe MJ, Sewankambo N et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. Engl. J. Med. 342(13), 921-929 (2000).
76. Mofenson LM, Lambert JS, Stiehm ER et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N. Engl. J. Med. 341(6), 385-393 (1999).
77. Lori F, Lisziewics J. Structured treatment interruptions for the management of HIV infection. JAMA 286(23), 2981-2987 (2001).
78. Ruiz L, Carcelain G, Martinz-Picado J et al. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 15, F19-F27 (2001).
79. Lawrence J, Mayers DL, Hullsiek KH et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N. Engl. J. Med. 349(9), 837-846 (2003).
80. Halfon P, Durant J, Clevenbergh P et al. Kinetics of disappearance of resistance mutations and reappearance of wild-type during structured treatment interruptions. AIDS 17(9), 1351-1361 (2003).
81. Oxenius A, Price DA, Gunthard HF et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc. Natl. Acad. Sci. USA. 99(21), 13747-13752 (2002).
82. Bucy RP, Moss RB, Gersten M et al. Therapeutic immunization with Remune alters kinetics of viral rebound after analytical therapy interruption. 9th Conference on Retroviruses and Oportunistic Infections, WA, USA, Abstract 314 (2002).
83. + lymphocyte numbers but does not enhance responses to immunization: results of A5046s. J. Infect. Dis. 187(2), 320-325 (2003).
84. Pido-Lopez J, Burtoc C, Hardy G et al. Thymic output during initial highly active antiretroviral tharapy (HAART) and during HAART supplementation with interleukin 2 and/or with HIV type 1 immunogen (Remune). AIDS Res. Hum. Retroviruses 19(2), 103-109 (2003).
85. Gotch FM, Hardy G, Imani N et al. The effects of immunotherapy with cytokine and/or vaccine in HAART treated patients. XIV International AIDS Conference on Clinical Aspects and Treatment of HIV infection, Barcelona, Spain. Abstract A1483 (2002).
86. Toma E, Loignon M, Zarowny D et al. Stopping antiretrovirals after therapy intensification, GM-CSF and initiation of therapeutic vaccination (remune) in chronic HIV disease results at 116 weeks. Sixth Int. Congress on Drug Therapy in HIV Infection, Glasgow, Scotland. Abstract P248 (2002).
87. Perrin L. Therapeutic vaccination in primary HIV infection, the Quest trial. Vaccine 20, 2004-2006 (2002).
88. Goh LE, Perrin L, Hoen B et al. Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: the QUEST study. HIV Clin. Trials 2(5), 438-444 (2001).
89. Moss RB, Diveley J, Jensen FC et al. Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA. J. Hum. Virol. 4, 39-43 (2001).
90. Ayash-Rashkovsky M, Weisman Z, Diveley J et al. Generation of Th1 immune responses to inactivated, gp120-depleted HIV-1 in mice with a dominant Th2 biased immune profile via immunostimulatory oligonucleotides-relevance to AIDS vaccines in developing countries. Vaccine 20, 2684-2692 (2002).
91. Dumais N, Patrick A, Moss RB et al. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J. Infect. Dis. 186(8), 1098-1105 (2002). Study in an animal model. Showed that mucosal immunization with REMUNE with a new adjuvant (CpG oligodeoxynucleotides) enhanced immunological protective responses against HIV-1 virus.
92. Blower S, Moss RB, Fernandez-Cruz E. Calculating the potential epidemic-level impact of therapeutic vaccination on the San Francisco HIV epidemic. AIDScience 3(21), (2003). Study designed a mathematical model and calculated the potential effectiveness of two types of vaccines in terms of the number of HIV infections prevented per year and the number of AIDS deaths prevented per year. This model used parameter values for the therapeutic vaccines based upon the clinical trial STIR 2102. The results suggest that therapeutic vaccination used in combination with ART could be useful in decreasing the HIV epidemic.